Nkarta, Inc.
Close on Oct 19, 2026
- Market cap
- $130.37M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Nkarta
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical organization focused on creating allogeneic, off-the-shelf engineered natural killer cell therapies. Its primary pipeline candidate, NKX019, is an engineered chimeric antigen receptor natural killer cell product designed to target the CD19 antigen. This lead candidate aims to treat various autoimmune conditions, including lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, and antineutrophil cytoplasmic antibody-associated vasculitis. It previously evaluated product candidates in oncology indications before redirecting its primary resources toward autoimmune diseases.
The organization operates two current good manufacturing practice facilities situated in South San Francisco, California. These internal facilities supply cell therapy products for ongoing and future clinical trials, with capacity planned to support potential commercial production. Clinical evaluations and investigator-sponsored trials involving its therapies take place across collaborating medical centers and universities within the United States.
Summary of the business section of Nkarta's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nkarta, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 1150 Veterans Boulevard 94080
- Phone
- (925) 407-1049
- Website
- nkartatx.com
- Employees
- 108, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, California
Stock & identifiers
- Ticker
- NKTX
- Exchange
- Nasdaq
- IPO date
- Jul 13, 2020
- Shares outstanding
- 72M, Aug 5, 2026
- Public float
- $82.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1787400
- CUSIP
- 65487U108
- ISIN
- US65487U1088
- EIN
- 47-4515206
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul J. Hastings | Chief Executive Officer, Director | 390,247 |
| Nadir Mahmood | President | 167,727 |
| Shawn Marshall Rose | See Remarks | 70,000 |
| Alicia J. Hager | Chief Legal Officer | 146,735 |
| Ralph Brandenberger | Chief Technical Officer | 124,796 |
| Alyssa Levin | See Remarks | 102,662 |
| David Shook | See Remarks | 190,955 |
| Capital Healthcare Fund LP RA | Director | – |
| Zachary Scheiner | Director | – |
| Leone D. Patterson | Director | – |
| Angela Thedinga | Director | – |
| George Vratsanos | Director | – |
| Michael Dybbs | Director | – |
| Rajeev M. Shah | Director | 7,805,129 |
| Peter Kolchinsky | Director | – |
| RA Capital Nexus Fund, L.P. | Director | – |
| Ra Capital Management, L.P. | Director | 10,050,818 |
| Simeon George | Director | 3,333,333 |
| Ali Behbahani | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Hastings | $2.98M | $2.04M | $1.31M | $28 | – |
| FY2024 Mr.Hastings | $3.99M | $1.54M | $2.62M | $38 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 108 full-time employees, 28 of whom have advanced degrees including but not limited to Ph.D., M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 13, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 2, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |